Genetic Testing Programs in Urology Empowering Patient Care
Chicago Marriott Magnificent Mile Hotel, Chicago, IL
November 14-16, 2024
Booth 406
As specialists dedicated to improving patient outcomes, we recognize the transformative power of genetic insights
in urologic care.
We invite you to explore how our advanced genetic testing solutions
are revolutionizing precision medicine in urology.

Unlock Genetic Insights in Prostate Cancer Care

  • Personalized Treatment Decisions

    Access actionable genetic data to tailor treatments specific to each patient's needs.

  • Enhanced Risk Assessment

    Utilize comprehensive genetic profiles to refine prognosis evaluations and risk stratification.

  • Empower Patients

    Provide patients with informed care plans based on their unique genetic makeup.

PROSTATENOW provides valuable insights in determining

a patient’s risk and potential treatment plans

Assess risk of developing prostate cancer
Family history, rare pathogenic mutations (RPMs) and genetic risk score (GRS) are three measures of inherited risk, allowing for a comprehensive analysis of risk of developing prostate cancer. Men with an increased risk of prostate cancer may consider earlier and more frequent prostate cancer screening and may evaluate their chances of passing on this risk to their offspring.
Assess prognosis for localized prostate cancer
ProstateNow supplements traditional clinical variables like Gleason score and PSA levels in determining risk for disease progression and can inform decisions on prostate cancer treatment, such as pursuing active surveillance versus definitive treatment with surgery or radiation.
Predict therapeutic responses for advanced prostate cancer
ProstateNow screens for pathogenic mutations in DNA repair genes and identifies patients who may respond better to targeted treatments, such as PARP inhibitors and platinum-based chemotherapies.

Leveraging data
to improve results

  • Reliability of RPMs and GRS in Multiple Races:

    • PROSTATENOW includes all known prostate cancer susceptibility genes
    • Includes >200 prostate cancer risk-associated SNPs for calculating GRS in multiple races

  • The Largest Mutation Database:

    • Following the guidelines of the American College of Medical Genetics (ACMG), we have the largest germline mutation database with data gathered from more than 300,000 men with or without prostate cancer.

Seamless Integration
into Clinical Practice

  • Effortless Implementation

    Integrate genetic testing smoothly into your existing workflow without disruption.

  • Streamlined Processes

    Benefit from an efficient testing procedure that saves time and resources.

  • Collaborative Care

    Work alongside genetic counselors to translate test results into meaningful patient care strategies.

Transform Patient Outcomes
with Actionable Data

  • Improved Treatment Efficacy

    Make informed decisions that enhance patient responses to therapy.

  • Proactive Family Care

    Identify hereditary risks to advise patients and their families on preventive measures.

  • Elevate Patient Satisfaction

    Enhance trust and satisfaction through personalized and precise care plans.

Results

Provide information and guidance related to a patient’s inherited mutation analysis. Results will both aid guidance on inherited risk and determine eligibility for response to PARPi inhibitors.

  • RPM results include

    · Pathogenic
    · Likely Pathogenic
    · Negative
    · Variants of Unknown Significance

  • ADT Implication (HSD3B1)

    · Present or not
    · Patient likelihood of response to ADT

  • GRS results include

    · Low
    · Intermediate
    · High
FDA-Cleared IVD Comprehensive
Genomic Profiling Panel
OncoTarget 500® is tissue-based, clinically, and analytically validated for all solid malignant neoplasms.
Learn more
Excellent Sensitivity and Specificity
Cleared For All Solid Malignant Neoplasms
30+ Validation Studies
FDA Cleared CE-IVD Marked Comprehensive Kitted Solution with Bioinformatics
Streamlined Workflow, Fast and Reliable
Excellent Results By A Large Prospective Study with Leading Academic Center​
Most hereditary cancers
This COMPREHENSIVE GERMLINE PANEL analyzes 88 clinically-relevant genes that are associated with genetic disorders, including most hereditary cancers.
Prostate cancer
PROSTATENOW is a germline test for people with prostate cancer. This test can be used to predict prognosis among men with localized prostate cancer, predict therapeutic responses for advanced patients, and predict cancer risk among unaffected men.
Breast cancer
There is an increased likelihood of a BRCA1 or BRCA2 mutation in patients with certain personal and family history characteristics and various clinical criteria. BRCANOW is a Next-Gen Sequencing (NGS)-based assay using a state-of-the-art platform to detect whether or not a mutation is present.
Colorectal cancer
LYNCHNOW is a cost-effective, screening tool that rapidly detects mutations that cause Lynch syndrome.
Diabetes
DIABETESNOW is a unique genetic panel that tests for 16 genes associated with MODY, syndromic, neonatal, and mitochondrial causes of monogenic diabetes. It also includes pan-ancestry type 1 and 2 diabetes polygenic risk scores (PRS) and the probability of type 1 diabetes (GenProb-T1D).
Discover how our Genetic Discovery Programs can enhance your practice and improve patient outcomes.
© GoPath Global, Inc. 2024 All rights reserved
Booth 406